Molecular Brain Research. The Laboratory of Molecular Brain Research investigates molecular mechanisms of neurodegeneration focusing on models of acute neurodegeneration (stroke, spinal cord injury) and chronic neurodegeneration (Alzheimer’s disease, Parkinson’s disease and Amyotrophic lateral sclerosis).
Dr. Jari Koistinaho, MD, PhD serves as the Chairman of the Board and President of Cerebricon Oy (Cerebricon Ltd.). Dr. Koistinaho has made significant contributions to biotech industry as a founder of two spin-off companies that initially were based on the scientific expertise of his research group.
Jari Koistinaho is a founder and scientific collaborator in Aranda’s CNS programs. Jari is an internationally recognized neuroscientist with over 200 peer-reviewed scientific publications in the field of neuroinflammation and neurodegeneration.
Molecular Brain Research // People Group leader Jari Koistinaho MD, PhD, Professor. Senior scientist, docent. Gundars Goldsteins Šárka Lehtonen. Post-doctoral fellows
Jari Koistinaho of University of Eastern Finland UEF with expertise in Neuroscience. Read 171 publications, and contact Jari Koistinaho on ResearchGate, the professional network for scientists.
Jari Koistinaho, PhD, MD Professor of Stem Cell Research, Professor of Pharmacology, Project Coordinator. The research group.
Lesions can affect the nervous system in many different ways and lead to more or less serious consequences. Our approach has over a …
The Rector of University of Helsinki has appointed Professor Jari Koistinaho as the new director of Neuroscience Center. The Center, operating within Helsinki Institute of Life Science HiLIFE, will move to Meilahti Campus at the beginning of 2018.
View Jari Koistinaho’s profile on LinkedIn, the world’s largest professional community. Jari has 1 job listed on their profile. See the complete profile on LinkedIn and discover Jari’s connections and jobs at similar companies.
Title: Professor at University of Kuopio
In the accompanying article, Koistinaho and colleagues studied whether variations in plasma glucose modulate the pattern of gene expression following cortical SD. Cortical SD by itself is not injurious, but, after cerebral ischemia, cortical SD–like events at the periphery of the infarct are thought to contribute to brain damage.